Recursion Pharmaceuticals, Inc. Class A Common Stock
RXRX US75629V1044
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-45% | -57% | 31% | -32% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Gibson Christopher CEO |
4.76 USD |
100,000 Sold |
476,000 USD |
25/09/2025 | 25/09/2025 |
Gibson Christopher CEO |
4.71 USD |
100,000 Sold |
471,000 USD |
10/09/2025 | 10/09/2025 |
Gibson Christopher CEO |
4.84 USD |
100,000 Sold |
484,000 USD |
26/08/2025 | 26/08/2025 |
Khan Najat SR OFF |
5.52 USD |
36,599 Sold |
202,173 USD |
15/08/2025 | 18/08/2025 |
Gibson Christopher CEO |
5.28 USD |
100,000 Sold |
528,000 USD |
11/08/2025 | 11/08/2025 |
Gibson Christopher CEO |
5.28 USD |
17,875 Sold |
94,380 USD |
11/08/2025 | 11/08/2025 |
Gibson Christopher CEO |
5.28 USD |
500,300 Sold |
2,641,584 USD |
11/08/2025 | 11/08/2025 |
Gibson Christopher CEO |
6.04 USD |
138,574 Sold |
836,987 USD |
27/03/2025 | 27/03/2025 |
Gibson Christopher CEO |
6.37 USD |
20,000 Sold |
127,400 USD |
05/03/2025 | 06/03/2025 |
Gibson Christopher CEO |
6.58 USD |
20,000 Sold |
131,600 USD |
05/03/2025 | 05/03/2025 |